Stay updated with breaking news from Abbvie Johnson. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Today, the U.S. Department of Health and Human Services made its initial offers to pharmaceutical companies pursuant to the Biden Administration’s Inflation Reduction Act, which allows the U.S. Government to “negotiate” Medicare drug prices.
Optimism must be balanced with conservative expectations given the unknown nature of the cost impact, says Mary N. Walsh.
Share it Medicaid could receive larger rebates from drugmakers beginning in 2024 under legislation signed Thursday by President Joe Biden — so large that some pharmaceutical companies could essentially end up paying states to use their drugs. The provision is tucked into the massive $1.9 trillion pandemic relief package and eliminates what's known as the Medicaid "penny rule." The obscure law has limited the mandatory rebates drugmakers pay to Medicaid to 100% of the average manufacturer price, or what wholesalers are charged after initial discounts. In the event required rebates total up t...